Precipio, Inc.
No enriched coverage for $PRPO in the last 7 days.
No SEC Form 4 filings for $PRPO in the last 30 days.
Precipio, a blood cancer diagnostics firm, announced a preliminary 23% increase in its fourth-quarter revenue. This short report, distributed by Reuters, highlights the company's Q4 financial performance.
PRPO reports strong third-quarter 2025 results with higher revenue, positive cash flow and improved margins in core divisions.
Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter ...
